Ammirati E, Frigerio M, Adler ED, Basso C, Birnie DH, Brambatti M, et al. Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document. Circ Heart Fail. 2020;13: e007405.
Article PubMed PubMed Central Google Scholar
Ferreira VM, Plein S, Wong TC, Tao Q, Raisi-Estabragh Z, Jain SS, et al. Cardiovascular magnetic resonance for evaluation of cardiac involvement in COVID-19: recommendations by the Society for Cardiovascular Magnetic Resonance. J Cardiovasc Magn Reson. 2023;25:21.
Article PubMed PubMed Central Google Scholar
Gluckman TJ, Bhave NM, Allen LA, Chung EH, Spatz ES, Ammirati E, et al. 2022 ACC expert consensus decision pathway on cardiovascular sequelae of COVID-19 in adults: myocarditis and other myocardial involvement, post-acute sequelae of SARS-CoV-2 infection, and return to play: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;79:1717–56.
Article CAS PubMed PubMed Central Google Scholar
Skali H, Schulman AR, Dorbala S. 18F-FDG PET/CT for the assessment of myocardial sarcoidosis. Curr Cardiol Rep. 2013;15:352.
Article PubMed PubMed Central Google Scholar
Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11:1305–23.
Terasaki F, Azuma A, Anzai T, Ishizaka N, Ishida Y, Isobe M, et al. JCS 2016 guideline on diagnosis and treatment of cardiac sarcoidosis - digest version. Circ J. 2019;83:2329–88.
Ahmadian A, Pawar S, Govender P, Berman J, Ruberg FL, Miller EJ. The response of FDG uptake to immunosuppressive treatment on FDG PET/CT imaging for cardiac sarcoidosis. J Nucl Cardiol. 2017;24:413–24.
Coulden RA, Sonnex EP, Abele JT, Crean AM. Utility of FDG PET and cardiac MRI in diagnosis and monitoring of immunosuppressive treatment in cardiac sarcoidosis. Radiol Cardiothorac Imaging. 2020;2: e190140.
Article PubMed PubMed Central Google Scholar
Osborne MT, Hulten EA, Singh A, Waller AH, Bittencourt MS, Stewart GC, et al. Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol. 2014;21:166–74.
Vaidyanathan S, Patel CN, Scarsbrook AF, Chowdhury FU. FDG PET/CT in infection and inflammation—current and emerging clinical applications. Clin Radiol. 2015;70:787–800.
Article CAS PubMed Google Scholar
Thackeray JT, Bengel FM. Molecular imaging of myocardial inflammation with positron emission yomography post-ischemia: a determinant of subsequent remodeling or recovery. JACC Cardiovasc Imaging. 2018;11:1340–55.
Stanley WC. Changes in cardiac metabolism: a critical step from stable angina to ischaemic cardiomyopathy. Eur Heart J. 2001;3:O2-7.
Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010;90:207–58.
Article CAS PubMed Google Scholar
Kang JY, Lee MY, Kim YH. Associations of physiologic myocardial 18F-FDG uptake with fasting duration, HbA1c, and regular exercise. Ann Nucl Med. 2021;35:195–202.
Article CAS PubMed Google Scholar
Inglese E, Leva L, Matheoud R, Sacchetti G, Secco C, Gandolfo P, et al. Spatial and temporal heterogeneity of regional myocardial uptake in patients without heart disease under fasting conditions on repeated whole-body F-18-FDG PET/CT. J Nucl Med. 2007;48:1662–9.
Chevreuil O, Hultin M, Ostergaard P, Olivecrona T. Depletion of lipoprotein lipase after heparin administration. Arterioscler Thromb. 1993;13:1391–6.
Article CAS PubMed Google Scholar
Ishida Y, Yoshinaga K, Miyagawa M, Moroi M, Kondoh C, Kiso K, et al. Recommendations for F-18-fluorodeoxyglucose positron emission tomography imaging for cardiac sarcoidosis: Japanese Society of Nuclear Cardiology Recommendations. Ann Nucl Med. 2014;28:393–403.
Kumita S, Yoshinaga K, Miyagawa M, Momose M, Kiso K, Kasai T, et al. Recommendations for 18F-fluorodeoxyglucose positron emission tomography imaging for diagnosis of cardiac sarcoidosis-2018 update: Japanese Society of Nuclear Cardiology recommendations. J Nucl Cardiol. 2019;26:1414–33.
Jang IK, Hursting MJ. When heparins promote thrombosis: review of heparin-induced thrombocytopenia. Circulation. 2005;111:2671–83.
Miyagawa M, Tashiro R, Watanabe E, Kawaguchi N, Ishimura H, Kido T, et al. Optimal patient preparation for detection and assessment of cardiac sarcoidosis by FDG-PET. Ann Nucl Cardiol. 2017;3:113–6.
Chareonthaitawee P, Beanlands RS, Chen W, Dorbala S, Miller EJ, Murthy VL, et al. Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. J Nucl Cardiol. 2017;24:1741–58.
Bois JP, Muser D, Chareonthaitawee P. PET/CT evaluation of cardiac sarcoidosis. PET Clin. 2019;14:223–32.
Chan SH, Huang CK, Luzhbin D, Hou PN, Chang YT, Wu J. Meta-analysis of the effectiveness of heparin in suppressing physiological myocardial FDG uptake in PET/CT. J Nucl Cardiol. 2023. https://doi.org/10.1007/s12350-023-03296-2.
Manabe O, Yoshinaga K, Ohira H, Masuda A, Sato T, Tsujino I, et al. The effects of 18-h fasting with low-carbohydrate diet preparation on suppressed physiological myocardial 18F-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis. J Nucl Cardiol. 2016;23:244–52.
Scholtens AM, van den Berk AM, van der Sluis NL, Esser JP, Lammers GK, de Klerk JMH, et al. Suppression of myocardial glucose metabolism in FDG PET/CT: impact of dose variation in heparin bolus pre-administration. Eur J Nucl Med Mol Imaging. 2020;47:2698–702.
Article CAS PubMed Google Scholar
Scholtens AM, Verberne HJ, Budde RP, Lam MG. Additional heparin preadministration improves cardiac glucose metabolism suppression over low-carbohydrate diet alone in 18F-FDG PET imaging. J Nucl Med. 2016;57:568–73.
Article CAS PubMed Google Scholar
Boursier C, Duval X, Bourdon A, Imbert L, Mahida B, Chevalier E, et al. ECG-gated cardiac FDG PET acquisitions significantly improve detectability of infective endocarditis. JACC Cardiovasc Imaging. 2020;13:2691–3.
Slart R, Glaudemans A, Gheysens O, Lubberink M, Kero T, Dweck MR, et al. Procedural recommendations of cardiac PET/CT imaging: standardization in inflammatory-, infective-, infiltrative-, and innervation (4Is)-related cardiovascular diseases: a joint collaboration of the EACVI and the EANM. Eur J Nucl Med Mol Imaging. 2021;48:1016–39.
Sahebkar A, Simental-Mendia LE, Pedone C, Ferretti G, Nachtigal P, Bo S, et al. Statin therapy and plasma free fatty acids: a systematic review and meta-analysis of controlled clinical trials. Br J Clin Pharmacol. 2016;81:807–18.
Article CAS PubMed PubMed Central Google Scholar
Minamimoto R. Series of myocardial FDG uptake requiring considerations of myocardial abnormalities in FDG-PET/CT. Jpn J Radiol. 2021;39:540–57.
Article PubMed PubMed Central Google Scholar
Liang JJ, Hebl VB, DeSimone CV, Madhavan M, Nanda S, Kapa S, et al. Electrogram guidance: a method to increase the precision and diagnostic yield of endomyocardial biopsy for suspected cardiac sarcoidosis and myocarditis. JACC Heart Fail. 2014;2:466–73.
Article PubMed PubMed Central Google Scholar
Simonen P, Lehtonen J, Kandolin R, Schildt J, Marjasuo S, Miettinen H, et al. F-18-fluorodeoxyglucose positron emission tomography-guided sampling of mediastinal lymph nodes in the diagnosis of cardiac sarcoidosis. Am J Cardiol. 2015;116:1581–5.
Terasaki F, Kusano K, Nakajima T, Yazaki Y, Morimoto SI, Culver DA, et al. The characteristics of Japanese guidelines on diagnosis and treatment of cardiac sarcoidosis compared with the previous guidelines. Sarcoidosis Vasc Diffuse Lung Dis. 2022;39: e2022028.
PubMed PubMed Central Google Scholar
Sato K, Kawamatsu N, Yamamoto M, Machino-Ohtsuka T, Ishizu T, Ieda M. Utility of updated Japanese Circulation Society Guidelines to diagnose isolated cardiac sarcoidosis. J Am Heart Assoc. 2022;11: e025565.
Article CAS PubMed PubMed Central Google Scholar
Saric P, Young KA, Rodriguez-Porcel M, Chareonthaitawee P. PET imaging in cardiac sarcoidosis: a narrative review with focus on novel PET tracers. Pharmaceuticals (Basel). 2021;14. https://doi.org/10.3390/ph14121286.
Kim SJ, Pak K, Kim K. Diagnostic performance of F-18 FDG PET for detection of cardiac sarcoidosis; a systematic review and meta-analysis. J Nucl Cardiol. 2020;27:2103–15.
Morimoto R, Unno K, Fujita N, Sakuragi Y, Nishimoto T, Yamashita M, et al. Prospective analysis of immunosuppressive therapy in cardiac sarcoidosis with fluorodeoxyglucose myocardial accumulation: PRESTIGE Study. JACC Cardiovasc Imaging. 2023. https://doi.org/10.1016/j.jcmg.2023.05.017.
Hassan K, Doubell A, Kyriakakis C, Joubert L, Robbertse PP, Van Zyl G, et al. Comparing the findings and diagnostic sensitivity of cardiovascular magnetic resonance in biopsy confirmed acute myocarditis with infarct-like vs. heart failure presentation. J Cardiovasc Magn Reson. 2022;24:69.
Comments (0)